See more : Shuz Tung Machinery Industrial Co., Ltd. (4537.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of CONX Corp. (CONX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CONX Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Multiexport Foods S.A. (MULTI-X.SN) Income Statement Analysis – Financial Results
- Snap Inc. (SNAP) Income Statement Analysis – Financial Results
- Global WholeHealth Partners Corporation (GWHP) Income Statement Analysis – Financial Results
- Canadian General Investments, Limited (CGI.TO) Income Statement Analysis – Financial Results
- Quartz Mountain Resources Ltd. (QZM.V) Income Statement Analysis – Financial Results
CONX Corp. (CONX)
Industry: Shell Companies
Sector: Financial Services
About CONX Corp.
CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.18K | 888.75K | 555.49K | 487.15 |
| Selling & Marketing | 1.18M | 0.00 | 0.00 | 161.89K |
| SG&A | 1.18M | 888.75K | 555.49K | 162.38K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Cost & Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Interest Income | 267.48K | 4.94M | 75.01K | 5.34K |
| Interest Expense | 0.00 | 4.94M | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | -21.36M | -19.86M | 5.34K |
| EBITDA | 0.00 | -888.75K | -20.41M | -162.38K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.18M | -888.75K | -555.49K | -162.38K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.75M | 26.30M | 19.93M | 2.28M |
| Income Before Tax | -5.93M | 25.41M | 19.37M | 2.12M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 65.47K | 1.21M | 18.45K | 1.12K |
| Net Income | -5.99M | 24.19M | 19.36M | 2.12M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.25 | 0.29 | 0.21 | 0.02 |
| EPS Diluted | -0.25 | 0.29 | 0.21 | 0.02 |
| Weighted Avg Shares Out | 23.80M | 82.98M | 93.77M | 93.76M |
| Weighted Avg Shares Out (Dil) | 23.80M | 82.98M | 93.77M | 93.76M |
CONX Corp. Announces Acquisition of Red Technologies SAS
CONX acquires a controlling interest in RED Technologies, a uniquely positioned "enabler" of Shared Spectrum and the nascent Private Network industry CONX appoints Marc Rouanne to the RED Technologies board LITTLETON, Colo. , Dec. 5, 2024 /PRNewswire/ -- CONX CORP.
Delisting of Securities of CONX Corp.; Priveterra Acquisition Corp. II; Yield10 Bioscience, Inc.; Aesthetic Medical International Holdings Group Ltd.; Breeze Holdings Acquisition Corp.; Quadro Acquisition One Corp.; DermTech, Inc.; TRACON Pharmaceuticals, Inc.; eFFECTOR Therapeutics, Inc.; Dynatronics Corporation; and Canna-Global Acquisition Corp. from The Nasdaq Stock Market
NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, units, and warrants of CONX Corp. CONX Corp.'s securities were suspended on May 6, 2024, and have not traded on Nasdaq since that time.
OTC Markets Group Welcomes CONX Corp. to OTCQX
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced CONX Corp. (OTCQX: CNXX; CNXXW) has qualified to trade on the OTCQX® Best Market....
CONX Corp. Announces Closing of Initial Business Combination
LITTLETON, Colo. , May 1, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or "CONX"), completed its previously announced transaction pursuant to the terms of the purchase and sale agreement (as amended by that amendment to the sale and...
CONX Corp. Announces Final Tender Offer Results
LITTLETON, Colo. , April 29, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or "CONX") announced today the final results of its previously announced tender offer (the "Tender Offer") to purchase up to 2,120,269 of its shares of Class...
CONX Corp. Announces Change in Tender Offer Price to Complete Business Combination
LITTLETON, Colo. , April 15, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or "CONX") announced today that it has changed the price to be paid in its previously announced tender offer (the "Tender Offer") to purchase up to...
CONX Corp. Announces Tender Offer to Complete Business Combination
LITTLETON, Colo. , April 1, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or "CONX") announced today that it has commenced a tender offer (the "Tender Offer") to purchase up to 2,120,269 of its shares of Class A common...
CONX Files Proxy Statement for Stockholders to Vote on Extension of Completion Period; Discloses Preliminary Discussions Regarding Business Combination
LITTLETON, Colo. , Oct. 12, 2022 /PRNewswire/ -- CONX, Corp. (Nasdaq: CONX, CONXU, CONXW) ("CONX" or the "Company") encourages stockholders to vote in favor of the proposal to amend CONX's articles of incorporation (the "Extension Amendment") to extend the date by...
Corgenix Receives FDA Authorization and WHO Listing for Emergency Use of Ebola Rapid Diagnostic Test
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB: CONX), a worldwide developer and marketer of diagnostic test kits, announced it has received U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) of its ReEBOV™ Antigen Rapid Test. The test is to be...
Corgenix Announces New Grants to Advance Work on Ebola Test Kit
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded two grants totaling $818,000 to advance the development of an Ebola rapid diagnostic test kit. The grants were awarded to Corgenix by...
Source: https://incomestatements.info
Category: Stock Reports